FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206714145> ?p ?o ?g. }

• W3206714145 abstract "Repurposing drugs provides a new approach to the fight against multidrug-resistant (MDR) bacteria. We have reported that three major tamoxifen metabolites, N-desmethyltamoxifen (DTAM), 4-hydroxytamoxifen (HTAM), and endoxifen (ENDX), presented bactericidal activity against Acinetobacter baumannii and Escherichia coli. Here, we aimed to analyze the activity of a mixture of the three tamoxifen metabolites against methicillin-resistant Staphylococcus epidermidis (MRSE) and Enterococcus species. MRSE (n = 17) and Enterococcus species (Enterococcus faecalis n = 8 and Enterococcus faecium n = 10) strains were used. MIC of the mixture of DTAM, HTAM, and ENDX and that of vancomycin were determined by microdilution assay. The bactericidal activity of the three metabolites together and of vancomycin against MRSE (SE385 and SE742) and vancomycin-resistant E. faecalis (EVR1 and EVR2) strains was determined by time-kill curve assays. Finally, changes in membrane permeability of SE742 and EVR1 strains were analyzed using fluorescence assays. MIC90 of tamoxifen metabolites was 1 mg/liter for MRSE strains and 2 mg/liter for E. faecalis and E. faecium strains. In the time-killing assays, tamoxifen metabolites mixture showed bactericidal activity at 4× MIC for MRSE (SE385 and SE742) and at 2× MIC and 4× MIC for E. faecalis (EVR1 and EVR2) strains, respectively. SE385 and EVR2 strains treated with the tamoxifen metabolites mixture presented higher membrane permeabilization. Altogether, these results showed that tamoxifen metabolites presented antibacterial activity against MRSE and vancomycin-resistant E. faecalis, suggesting that tamoxifen metabolites might increase the arsenal of drug treatments against these bacterial pathogens. IMPORTANCE The development of new antimicrobial therapeutic strategies requires immediate attention to avoid the tens of millions of deaths predicted to occur by 2050 as a result of MDR bacterial infections. In this study, we assessed the antibacterial activity of three major tamoxifen metabolites, N-desmethyltamoxifen (DTAM), 4-hydroxytamoxifen (HTAM), and endoxifen (ENDX), against methicillin-resistant Staphylococcus epidermidis (MRSE) and Enterococcus spp. (E. faecalis and E. faecium). We found that the tamoxifen metabolites have antibacterial activity against MRSE, E. faecalis, and E. faecium strains by presenting MIC90 between 1 and 2 mg/liter and bactericidal activity over 24 h. In addition, this antibacterial activity is paralleled by an increased membrane permeability of these strains. Our results showed that tamoxifen metabolites might be potentially used as a therapeutic alternative when treating MRSE and E. faecalis strains in an animal model of infection." @default.
• W3206714145 created "2021-10-25" @default.
• W3206714145 creator A5000460017 @default.
• W3206714145 creator A5016077959 @default.
• W3206714145 creator A5022362699 @default.
• W3206714145 creator A5032854210 @default.
• W3206714145 creator A5065820139 @default.
• W3206714145 creator A5076347067 @default.
• W3206714145 creator A5080377178 @default.
• W3206714145 date "2021-10-31" @default.
• W3206714145 modified "2023-10-03" @default.
• W3206714145 title "Repurposing of the Tamoxifen Metabolites to Treat Methicillin-Resistant Staphylococcus epidermidis and Vancomycin-Resistant Enterococcus faecalis Infections" @default.
• W3206714145 cites W1270356811 @default.
• W3206714145 cites W1479918971 @default.
• W3206714145 cites W1970448606 @default.
• W3206714145 cites W1991471402 @default.
• W3206714145 cites W2028598078 @default.
• W3206714145 cites W2032341525 @default.
• W3206714145 cites W2042985928 @default.
• W3206714145 cites W2121890370 @default.
• W3206714145 cites W2129636343 @default.
• W3206714145 cites W2133507954 @default.
• W3206714145 cites W2148427024 @default.
• W3206714145 cites W2154581429 @default.
• W3206714145 cites W2162924609 @default.
• W3206714145 cites W2253526228 @default.
• W3206714145 cites W2330648490 @default.
• W3206714145 cites W2411147914 @default.
• W3206714145 cites W2549280062 @default.
• W3206714145 cites W2738909163 @default.
• W3206714145 cites W2807412359 @default.
• W3206714145 cites W2902895976 @default.
• W3206714145 cites W2904382879 @default.
• W3206714145 cites W2954196080 @default.
• W3206714145 cites W2990957197 @default.
• W3206714145 cites W2999108002 @default.
• W3206714145 cites W3014667439 @default.
• W3206714145 cites W3130162076 @default.
• W3206714145 cites W3137689425 @default.
• W3206714145 cites W3165219347 @default.
• W3206714145 cites W4256678545 @default.
• W3206714145 cites W859864464 @default.
• W3206714145 doi "https://doi.org/10.1128/spectrum.00403-21" @default.
• W3206714145 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8528103" @default.
• W3206714145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34668743" @default.
• W3206714145 hasPublicationYear "2021" @default.
• W3206714145 type Work @default.
• W3206714145 sameAs 3206714145 @default.
• W3206714145 citedByCount "1" @default.
• W3206714145 countsByYear W32067141452023 @default.
• W3206714145 crossrefType "journal-article" @default.
• W3206714145 hasAuthorship W3206714145A5000460017 @default.
• W3206714145 hasAuthorship W3206714145A5016077959 @default.
• W3206714145 hasAuthorship W3206714145A5022362699 @default.
• W3206714145 hasAuthorship W3206714145A5032854210 @default.
• W3206714145 hasAuthorship W3206714145A5065820139 @default.
• W3206714145 hasAuthorship W3206714145A5076347067 @default.
• W3206714145 hasAuthorship W3206714145A5080377178 @default.
• W3206714145 hasBestOaLocation W32067141453 @default.
• W3206714145 hasConcept C176947019 @default.
• W3206714145 hasConcept C185592680 @default.
• W3206714145 hasConcept C2776315533 @default.
• W3206714145 hasConcept C2777637488 @default.
• W3206714145 hasConcept C2777677444 @default.
• W3206714145 hasConcept C2777949923 @default.
• W3206714145 hasConcept C2778980435 @default.
• W3206714145 hasConcept C2779489039 @default.
• W3206714145 hasConcept C2779895986 @default.
• W3206714145 hasConcept C2780585763 @default.
• W3206714145 hasConcept C2780950330 @default.
• W3206714145 hasConcept C4937899 @default.
• W3206714145 hasConcept C501593827 @default.
• W3206714145 hasConcept C523546767 @default.
• W3206714145 hasConcept C54355233 @default.
• W3206714145 hasConcept C86803240 @default.
• W3206714145 hasConcept C89423630 @default.
• W3206714145 hasConceptScore W3206714145C176947019 @default.
• W3206714145 hasConceptScore W3206714145C185592680 @default.
• W3206714145 hasConceptScore W3206714145C2776315533 @default.
• W3206714145 hasConceptScore W3206714145C2777637488 @default.
• W3206714145 hasConceptScore W3206714145C2777677444 @default.
• W3206714145 hasConceptScore W3206714145C2777949923 @default.
• W3206714145 hasConceptScore W3206714145C2778980435 @default.
• W3206714145 hasConceptScore W3206714145C2779489039 @default.
• W3206714145 hasConceptScore W3206714145C2779895986 @default.
• W3206714145 hasConceptScore W3206714145C2780585763 @default.
• W3206714145 hasConceptScore W3206714145C2780950330 @default.
• W3206714145 hasConceptScore W3206714145C4937899 @default.
• W3206714145 hasConceptScore W3206714145C501593827 @default.
• W3206714145 hasConceptScore W3206714145C523546767 @default.
• W3206714145 hasConceptScore W3206714145C54355233 @default.
• W3206714145 hasConceptScore W3206714145C86803240 @default.
• W3206714145 hasConceptScore W3206714145C89423630 @default.
• W3206714145 hasFunder F4320334923 @default.
• W3206714145 hasIssue "2" @default.
• W3206714145 hasLocation W32067141451 @default.
• W3206714145 hasLocation W32067141452 @default.
• W3206714145 hasLocation W32067141453 @default.
• W3206714145 hasLocation W32067141454 @default.
• W3206714145 hasLocation W32067141455 @default.

• next